Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Update and latest advances in antiretroviral therapy
Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …
1) infection has reached pandemic proportions. Forty years later, research has led to the …
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance
Antiretroviral therapy has been imperative in controlling the human immunodeficiency virus
(HIV) epidemic. Most low-and middle-income countries have used nucleoside reverse …
(HIV) epidemic. Most low-and middle-income countries have used nucleoside reverse …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel
Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA Panel
Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …
Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3-or 4-drug regimen for maintaining virologic suppression in adults …
Background In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-
term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment …
term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic …
O Osiyemi, S De Wit, F Ajana, F Bisshop… - Clinical Infectious …, 2022 - academic.oup.com
Background Switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing
tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week …
tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week …
[HTML][HTML] Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
Antiretrovirals and weight change: weighing the evidence
Body weight is influenced by an interplay of individual and environmental factors. In people
with human immunodeficiency virus (HIV), weight is also influenced by disease status with …
with human immunodeficiency virus (HIV), weight is also influenced by disease status with …
Two-drug regimens for HIV treatment
Combination therapy with three antiretroviral agents has been integral to successful HIV-1
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …